Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab
| Autor: | Luca Idolazzi, Elena Fracassi, Ombretta Viapiana, Maurizio Rossini, Davide Gatti, Silvano Adami, C. Dartizio, Maria Rosaria Povino |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Genetic Markers
medicine.medical_specialty Endocrinology Diabetes and Metabolism Osteoporosis Antibodies Monoclonal Humanized Placebo Collagen Type I Bone resorption Bone remodeling chemistry.chemical_compound N-terminal telopeptide Bone Density Internal medicine Humans Medicine Orthopedics and Sports Medicine Osteoporosis Postmenopausal Adaptor Proteins Signal Transducing Aged Demography Hip Bone Density Conservation Agents biology business.industry Alkaline Phosphatase medicine.disease Spine Denosumab Endocrinology chemistry RANKL Bone Morphogenetic Proteins biology.protein Intercellular Signaling Peptides and Proteins Sclerostin Female Peptides business Biomarkers medicine.drug |
| Zdroj: | Journal of Bone and Mineral Research. 27:2259-2263 |
| ISSN: | 0884-0431 |
| DOI: | 10.1002/jbmr.1681 |
| Popis: | The bone mass benefits of antiresorbers in postmenopausal osteoporosis are limited by the rapid coupling of decreasing bone resorption with bone formation. Wnt signaling is involved in this coupling process during treatment with bisphosphonates, whereas its role during treatment with the anti-receptor activator of NF-κB ligand (RANKL) antibody denosumab is unknown. The study population includes patients participating in a placebo-controlled trial lasting 36 months: 19 women were on placebo and 24 on subcutaneous 60 mg denosumab every 6 months. All measured parameters (serum C-terminal telopeptide of type I collagen [sCTX], serum bone alkaline phosphatase [bAP], Dickkopf-1 [DKK1], and sclerostin) remained unchanged during the observation period in the placebo group. sCTX and bAP were significantly suppressed by denosumab treatment over the entire follow-up. Denosumab treatment was associated with significant (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text